- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Shares of GW Pharmaceuticals Skyrocket on Successful Cannabis Drug Trial
Reuters reported on Monday that shares of GW Pharmaceuticals (NASDAQ:GWPH) more than doubled in value on Monday after the company released promising test results for an experimental marijuana drug.
Reuters reported on Monday that shares of GW Pharmaceuticals (NASDAQ:GWPH) more than doubled in value on Monday after the company released promising test results for an experimental marijuana drug.
As quoted in the publication:
Following positive results in the first Phase 3 study of its investigational medicine Epidiolex, GW Pharma’s stock popped by 139 percent intraday. While GW Pharma grows marijuana, it only extracts a non psychoactive component of the plant called CBD.
The experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial. Analysts, on average, believe the drug could generate annual sales of $1.1 billion by 2021, according to consensus forecasts compiled by Thomson Reuters Cortellis.
Outlook Reports
Featured Cannabis Investing News Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2383.98 | +4.05 | |
Silver | 28.35 | +0.11 | |
Copper | 4.49 | +0.02 | |
Oil | 83.21 | +0.48 | |
Heating Oil | 2.54 | -0.01 | |
Natural Gas | 1.74 | -0.01 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.